Abstract
A series of hexahydroindazole analogues of curcumin were synthesized and investigated for in vitro and in silico antimicrobial activity. The structures of synthesized compounds were identified on the basis of satisfactory analytical and spectral data (1H NMR, 13C NMR, EI-MASS techniques and elemental analysis). Synthesized compounds showed moderate to high activity against both bacterial and fungal strains. All compounds were docked computationally to the active site of enzyme L-glutamine: D-fructose-6-phosphate amido-transferase [GlcN-6-P] (EC 2.6.1.16). The autodock programme 4.0 was employed to perform automated molecular docking. (E)-1-(7-(3-methoxybenzylidene)-3-(3- methoxyphenyl)-3,3a,4,5,6,7-hexahydro-2H-indazol-2-yl)ethanone (A7) turned out to be the most potent analogue of the series, showing best activity against bacterial and fungal strains. Compound A7 showed minimum binding and docking energy and may be considered as good inhibitor of GlcN-6-P synthase. Further investigation and optimization of this lead could provide new antimicrobial molecules.
Keywords: Autodock 4.0, Bacterial strain, Fungal strains, GlcN-6-P synthase, Hexahydroindazole, In silico, cycloheaxanon, glacial acetic acid, ethlyl alcohol, Candida
Letters in Drug Design & Discovery
Title:Synthesis, Molecular Docking and In Vitro Antimicrobial Studies of New Hexahydroindazole Derivatives of Curcumin
Volume: 10 Issue: 2
Author(s): Dileep Kumar, Harish B.G, Mayank Gangwar, Manish Kumar, Dharmendra Kumar, RaginiTilak, Gopal Nath, Ashok kumar and Sushil Kumar Singh
Affiliation:
Keywords: Autodock 4.0, Bacterial strain, Fungal strains, GlcN-6-P synthase, Hexahydroindazole, In silico, cycloheaxanon, glacial acetic acid, ethlyl alcohol, Candida
Abstract: A series of hexahydroindazole analogues of curcumin were synthesized and investigated for in vitro and in silico antimicrobial activity. The structures of synthesized compounds were identified on the basis of satisfactory analytical and spectral data (1H NMR, 13C NMR, EI-MASS techniques and elemental analysis). Synthesized compounds showed moderate to high activity against both bacterial and fungal strains. All compounds were docked computationally to the active site of enzyme L-glutamine: D-fructose-6-phosphate amido-transferase [GlcN-6-P] (EC 2.6.1.16). The autodock programme 4.0 was employed to perform automated molecular docking. (E)-1-(7-(3-methoxybenzylidene)-3-(3- methoxyphenyl)-3,3a,4,5,6,7-hexahydro-2H-indazol-2-yl)ethanone (A7) turned out to be the most potent analogue of the series, showing best activity against bacterial and fungal strains. Compound A7 showed minimum binding and docking energy and may be considered as good inhibitor of GlcN-6-P synthase. Further investigation and optimization of this lead could provide new antimicrobial molecules.
Export Options
About this article
Cite this article as:
Kumar Dileep, B.G Harish, Gangwar Mayank, Kumar Manish, Kumar Dharmendra, RaginiTilak , Nath Gopal, kumar Ashok and Kumar Singh Sushil, Synthesis, Molecular Docking and In Vitro Antimicrobial Studies of New Hexahydroindazole Derivatives of Curcumin, Letters in Drug Design & Discovery 2013; 10 (2) . https://dx.doi.org/10.2174/157018013804725161
DOI https://dx.doi.org/10.2174/157018013804725161 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Revisiting the Paris Declaration: Pharmacogenomics and Personalized Medicine as Accelerators for Development Aid and Effectiveness]
Current Pharmacogenomics and Personalized Medicine Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Imaging the Earliest Stages of Alzheimers Disease
Current Alzheimer Research Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Detection of <i>Streptococcus pneumoniae</i> in Sputum Samples by Real-Time PCR
Anti-Infective Agents Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care
Current Drug Metabolism Aminoglycoside-Induced Ototoxicity
Current Pharmaceutical Design Mannose-Binding Lectin Protein Deficiency Among Patients with Primary Immunodeficiency Disease Receiving IVIG Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology Lantibiotic Production by Pathogenic Microorganisms
Current Protein & Peptide Science Corticosteroids in Sepsis: Pathophysiological Rationale and the Selection of Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Inflammatory Adjuvant Agents in Bacterial Meningitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS)
Current HIV Research Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Biology of gama delta T Cells in Tuberculosis and Malaria
Current Molecular Medicine Anatomical and Functional Relationships Between Sensory Nerves and Mast Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Sulfonamides: Antiviral Strategy for Neglected Tropical Disease Virus
Current Organic Chemistry